Table 1.
Demographics of PASC participants.
| Variable |
Test confirmed (N = 1,249, %) |
Test unconfirmed (N = 1,065, %) |
|---|---|---|
| Female | 1,079 (86.4%) | 941 (88.4%) |
| Male | 170 (13.6%) | 124 (11.6%) |
| Age (years) | ||
| Age 18–30 | 182 (14.6%) | 126 (11.8%) |
| Age 31–45 | 494 (39.6%) | 457 (43%) |
| Age 46–65 | 573 (45.9%) | 482 (45.3%) |
| Race/Ethnicity* | ||
| White | 1,099 (88%) | 972 (91.3%) |
| Hispanic | 69 (5.5%) | 36 (3.4%) |
| Asian | 42 (3.4%) | 43 (4%) |
| Native American/Indian | 28 (2.2%) | 27 (2.5%) |
| Black | 28 (2.4%) | 14 (1.3%) |
| Middle Eastern | 11 (1 %) | 12 (1.1%) |
| Hawaiian/Pacific Islander | 6 (0.5%) | 1 (0.1%) |
| Biracial/Multiracial | 35 (2.8%) | 36 (3.4%) |
| Not disclosed/unknown | 17(1.4%) | 17 (1.6%) |
| Average BMI** | ||
| Underweight (< 18.5) | 41 (3.3%) | 60 (5.6%) |
| Normal (18.5–24.9) | 421 (33.7%) | 484 (45.4%) |
| Overweight (25–29.9) | 316 (25.3%) | 277 (26%) |
| Obese (30 and above) | 456 (36.6%) | 228 (21.4%) |
| Time from symptom onset to survey completion | ||
| 30 days−3 months | 426 (34.1%) | 49 (4.6%) |
| 3–6 months | 359 (28.7%) | 138 (13%) |
| 6–9 months | 352 (28.2%) | 584 (54.8%) |
| 9 months and greater | 112 (9%) | 294 (27.6%) |
| Testing Status | ||
| Self-suspected (no test) | 0 | 388 (36.4%) |
| Physician diagnosed (no test) | 0 | 677 (63.6%) |
| Symptoms only | 0 | 1,065 (100%) |
| Diagnostic (RT-PCR/antigen) | 899 (72%) | 0 |
| Antibody (IgG, IgM or both) | 143 (11.4%) | 0 |
| Diagnostic and antibody | 207 (16.6%) | 0 |
| COVID Severity | ||
| No hospital admission | 1,069 (86%) | 982 (92.2%) |
| Hospital admission | 180 (14.4%) | 83 (7.8%) |
| ICU admission | 41 (3.3 %) | 5 (0.5%) |
| Intubated | 12 (1%) | 2 (0.2%) |
| Supplemental oxygen | 134 (10.7%) | 46 (4.3%) |
| Countries of residence*** | ||
| USA | 1,069 (85.6%) | 727 (68.3%) |
| United Kingdom | 26 (2.1%) | 128 (12%) |
| Canada | 28 (2.2%) | 103 (9.7%) |
| Germany | 27 (2.2%) | 10 (0.9%) |
| Sweden | 6 (0.5%) | 17 (1.6%) |
*Some respondents checked more than 1 category, **Some data was incomplete (N = 1,234 testing confirmed, N = 1,049 testing unconfirmed), ***Participants from 34 countries responded to the survey, only countries with a respondence rate of 1% of greater are listed.